Chicago Biomedical Consortium
A multi-institutional nonprofit consortium that funds and coordinates cross-university biomedical research and translational programs in the Chicagoland region. Core activities include milestone-driven seed and matching funding for translational and basic research, entrepreneurship training, rapid-response public-health awards, facilitation and funding support for shared core facilities and instrumentation, organization of symposia/courses/workshops, and advisory review processes that connect academic teams with industry and investor expertise to advance early-stage discoveries toward commercialization.
Industries
N/A
Nr. of Employees
small (1-50)
Services
Milestone-driven direct-cost awards to support translational projects aimed at therapeutics, diagnostics, or enabling technologies.
Collaborative awards to enable interdisciplinary projects addressing mechanistic or methodological challenges in biomedical science.
Fellowship program that trains early-career researchers in commercialization and connects them with mentors and the regional biotech ecosystem.
Matching funds and administrative support for multi-institution center proposals and infrastructure projects to establish shared research centers and cores.
Funding and programmatic support to establish and operate cores (nanocytometry, PDX core, advanced genomics, quantitative element imaging) and provide technical instruction and subsidized access.
Production and provision of research-grade viral vectors and advisory support for gene delivery and gene-therapy study design on a subsidized, fee-for-service basis.
Milestone-driven direct-cost awards to support translational projects aimed at therapeutics, diagnostics, or enabling technologies.
Collaborative awards to enable interdisciplinary projects addressing mechanistic or methodological challenges in biomedical science.
Fellowship program that trains early-career researchers in commercialization and connects them with mentors and the regional biotech ecosystem.
Matching funds and administrative support for multi-institution center proposals and infrastructure projects to establish shared research centers and cores.
Funding and programmatic support to establish and operate cores (nanocytometry, PDX core, advanced genomics, quantitative element imaging) and provide technical instruction and subsidized access.
Production and provision of research-grade viral vectors and advisory support for gene delivery and gene-therapy study design on a subsidized, fee-for-service basis.
Expertise Areas
- Translational research acceleration
- Early-stage and milestone-driven funding management
- Academic–industry partnership facilitation
- Entrepreneurship training and commercialization mentorship
Key Technologies
- Cryo-electron microscopy
- Scanning transmission electron microscopy with elemental mapping
- Top-down mass spectrometry for proteomics
- Next-generation sequencing
News & Updates
Provided expedited awards in September 2020 supporting studies on severe COVID-19 immune responses, vaccine-efficacy strategies using nanomaterials, and small-molecule inhibitors targeting SARS‑CoV‑2 viral enzymes; awards ranged around $498k–$500k.
Awarded a lever/matching grant (~$1.49M) to support the Chicago Center for Physical Science-Oncology Innovation and Translation and to fund shared cores including nanocytometry and PDX resources.
Provided a $2.32M matching Lever Award to support a tri-institutional center for production of synthetic affinity reagents integrated with an NIH U54 program.
Funding awarded to support preclinical work on a tri-specific T cell engager targeting glioblastoma to accelerate lead selection for clinical translation.
Funded collaborative cryo-EM structural studies of tight junction proteins to inform therapeutic targeting of epithelial barrier defects.
Appointed a Scientific Director for the University of Illinois at Chicago to represent the consortium within the institution and to guide Phase 2 programming (announcement June 2018).
Provided expedited awards in September 2020 supporting studies on severe COVID-19 immune responses, vaccine-efficacy strategies using nanomaterials, and small-molecule inhibitors targeting SARS‑CoV‑2 viral enzymes; awards ranged around $498k–$500k.
Awarded a lever/matching grant (~$1.49M) to support the Chicago Center for Physical Science-Oncology Innovation and Translation and to fund shared cores including nanocytometry and PDX resources.
Provided a $2.32M matching Lever Award to support a tri-institutional center for production of synthetic affinity reagents integrated with an NIH U54 program.
Funding awarded to support preclinical work on a tri-specific T cell engager targeting glioblastoma to accelerate lead selection for clinical translation.
Funded collaborative cryo-EM structural studies of tight junction proteins to inform therapeutic targeting of epithelial barrier defects.
Appointed a Scientific Director for the University of Illinois at Chicago to represent the consortium within the institution and to guide Phase 2 programming (announcement June 2018).